CTOs on the Move


 
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cyteir.com
  • 128 Spring Street Building A, Suite 510
    Lexington, MA USA 02421
  • Phone: 857.285.4140

Executives

Name Title Contact Details

Funding

Cyteir raised $29M on 03/08/2018
Cyteir raised $40.2M on 10/15/2019
Cyteir raised $80M on 02/11/2021

Similar Companies

Giving Home Health Care

We provide in-home health care for those with illnesses contracted while working in nuclear energy programs.

Maat Nutritionals

Maat Nutritionals is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PHC Holdings

This is the website of PHC Holdings Corporation, which is a global innovator in healthcare solutions.

CuraScript

CuraScript is one of the nation's largest providers of specialty injectable and oral medications. CuraScript has been in the specialty pharmacy business since 1989. Between 1994 and August 1, 2000, the company operated as Coram Prescription Services

EndoSound

Transforming the economics, usability, and accessibility of Endoscopic Ultrasound (EUS) for the benefit of patients, physicians, and payers.